Thin
1 / 2
Tirzepatide is specially designed to target two key receptors in the body: glucose-dependent insulin secretagogue polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism of action enables Tirzepatide to simultaneously address multiple aspects of metabolic health, providing a comprehensive solution for people who have difficulty managing their weight.
Tirzepatide is a dual GLP-1/GIP receptor agonist designed to improve glycemic control, reduce body weight, and support overall metabolic health. It has been studied extensively in clinical trials for type 2 diabetes and obesity management.
Tirzepatide (brand names include Mounjaro®/Zepbound®) is used for glycemic control and weight management, administered as a once‑weekly subcutaneous injection. Available strengths typically include: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per dose, adjusted based on clinical response and tolerability.
Tirzepatide is specially designed to target two key receptors in the body: glucose-dependent insulin secretagogue polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.
By acting as a dual GLP-1/GIP receptor agonist, it simultaneously addresses multiple aspects of metabolic health to improve glycemic control and reduce body weight.
It has been studied extensively in clinical trials and is primarily used for type 2 diabetes management and obesity/weight management.
Tirzepatide is administered as a once‑weekly subcutaneous injection.
Available strengths typically include 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per dose, which are adjusted based on clinical response and tolerability.
